Search research articles
Contact Us
Filters
Showing results (231-240 of 249) with videos related to
Page
of 25
Sort By:
Lancet (London, England)
|
April 16, 2016
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag, Serge Koscielny, Jacques Bosq, et al.
Blood
|
May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
Mitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2007
Revised response criteria for malignant lymphoma
Bruce D Cheson, Beate Pfistner, Malik E Juweid, et al.
Blood
|
January 29, 2011
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
Dennis D Weisenburger, Kerry J Savage, Nancy Lee Harris, et al.
The Lancet. Oncology
|
February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.
Blood
|
May 14, 2011
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project
Jan Delabie, Harald Holte, Julie M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P Sharman, Steven E Coutre, Richard R Furman, et al.
The Lancet. Haematology
|
November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
Michinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network
Eva Hoster, Andreas Rosenwald, Françoise Berger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 21, 2017
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 249) with videos related to
Sort By:
Page
of 25
Lancet (London, England)
|
April 16, 2016
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag, Serge Koscielny, Jacques Bosq, et al.
Blood
|
May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
Mitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2007
Revised response criteria for malignant lymphoma
Bruce D Cheson, Beate Pfistner, Malik E Juweid, et al.
Blood
|
January 29, 2011
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
Dennis D Weisenburger, Kerry J Savage, Nancy Lee Harris, et al.
The Lancet. Oncology
|
February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.
Blood
|
May 14, 2011
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project
Jan Delabie, Harald Holte, Julie M Vose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P Sharman, Steven E Coutre, Richard R Furman, et al.
The Lancet. Haematology
|
November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
Michinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network
Eva Hoster, Andreas Rosenwald, Françoise Berger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 21, 2017
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, et al.
Page
of 25